| Literature DB >> 30180205 |
Sangwoo Lee1, Hang-Suk Chun1, Jieon Lee1, Han-Jin Park2, Ki-Tae Kim3, Cheol-Hee Kim4, Seokjoo Yoon1, Woo-Keun Kim1.
Abstract
Autism spectrum disorder (ASD) is a serious neurodevelopmental disorder characterized by impaired or abnormal social interaction and communication and by restricted and repetitive behaviour. ASD is highly prevalent in Asia, Europe, and the United States, and the frequency of ASD is growing each year. Recent epidemiological studies have indicated that ASD may be caused or triggered by exposure to chemicals in the environment, such as those in the air or water. Thus, toxicological studies are needed to examine chemicals that might be implicated. However, the experimental efficiency of existing experimental models is limited, and many models represent challenges in terms of animal welfare. Thus, alternative ASD animal models are necessary. To address this, we examined the efficacy of the zebrafish embryo/larva as an alternative model of ASD. Specifically, we exposed zebrafish to valproic acid (0, 12.5, 25, 50, or 100 μM), which is a chemical known to induce autism-like effects. We then analysed subsequent developmental, behavioural, and transcriptomic changes. We found that 100 μM and 50 μM valproic acid decreased the hatching rate and locomotor activity of zebrafish embryos/larvae. Transcriptomic analysis revealed significant alterations in a number of genes associated with autism, such as adsl, mbd5, shank3, and tsc1b. Additionally, we found changes in gene ontology that were also reported in previous studies. Our findings indicate that zebrafish embryos/larvae and humans with ASD might have common physiological pathways, indicating that this animal model may represent an alternative tool for examining the causes of and potential treatments for this illness.Entities:
Mesh:
Year: 2018 PMID: 30180205 PMCID: PMC6122816 DOI: 10.1371/journal.pone.0203543
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Commonly observed ASD-related DEGs in this and previous studies.
| Genes suggested by previous human studies | Description | |||||
|---|---|---|---|---|---|---|
| Voineagu | Pinto | Sanders et al. (2015) | Bourgeron | Chang | ||
| alpha-actinin-4 | ||||||
| calcium-activate neutral proteinase 12 | ||||||
| dicarbonyl/L-xylulose reductase | ||||||
| damage-specific DNA binding protein 1 | ||||||
| eukaryotic translation initiation factor 4A1A | ||||||
| fanconi anaemia group A protein | ||||||
| guanidinoacetate N-methyltransferase | ||||||
| glycine amidinotransferase | ||||||
| hydroxysteroid (17-beta) dehydrogenase 10 | ||||||
| potassium inwardly rectifying channel, subfamily J, member 11 | ||||||
| myosin, heavy chain 11a, smooth muscle | ||||||
| neurexin-2 | ||||||
| high affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A | ||||||
| 6-phosphofructokinase, muscle type | ||||||
| retinal pigment epithelium-specific protein 65a | ||||||
| ribosomal protein L10 | ||||||
| solute carrier family 6, member 1, like | ||||||
| succinate-CoA ligase, GDP-forming, beta subunit | ||||||
| tryptophan 2,3-dioxygenase a | ||||||
| thyroid hormone receptor interactor 12 | ||||||
a) Review article. DEGs were determined based on statistical significance (p < 0.05). Fold changes (log2FC) for each DEG are shown in S3–S7 Tables. DEGs from multiple studies are marked in bold.
Fig 1Effects of VPA on zebrafish survival, hatching status, and development.
NA: not available due to significantly decreased hatching rate. The results are shown as the mean ± standard deviation (N = 4). Asterisk (*) denotes statistical significance (p < 0.05).
Fig 2Total distance moved (a) and active duration ratio (b) after 120 h VPA exposure. The error bars are marked separately for the dark and light phases. The analysis the total distance moved was determined for the sum of the distance moved during the dark and light phases. The results are shown as the mean ± SEM (N = 8, except control (N = 7)). Asterisks (*) indicate statistical significance (p < 0.05).
Fig 3Commonality of (a) DEGs and (b) GOs in the present study with respect to previous studies. (a) Data from Voineagu et al. (2011), Pinto et al. (2014), Sanders et al. (2015), Bourgeron et al. (2015), and Chang et al. (2015). (b) Data from Chang et al. (2015) and Jasien et al. (2014).
Fig 4Gene transcription confirmation by using qRT-PCR analysis.
The results are shown as the mean ± SEM (N = 4). Asterisks (*) and arrows indicate significant differences from the control and significant trend of the slope, respectively (p < 0.05).
Commonly observed GO enrichments in this and previous studies.
| Chang | Jasien | Term. | ||
|---|---|---|---|---|
| Cortical | Hippocampal | |||
| BP | GO:0006091 | generation of precursor metabolites and energy | ||
| BP | GO:0006397 | mRNA processing | ||
| BP | ||||
| BP | GO:0006873 | cellular ion homeostasis | ||
| BP | GO:0016071 | mRNA metabolic process | ||
| BP | GO:0022904 | respiratory electron transport chain | ||
| BP | GO:0044281 | small molecule metabolic process | ||
| BP | GO:0045333 | cellular respiration | ||
| BP | GO:0048729 | tissue morphogenesis | ||
| CC | ||||
| CC | ||||
| CC | ||||
| CC | GO:0005743 | mitochondrial inner membrane | ||
| CC | GO:0005746 | mitochondrial respiratory chain | ||
| CC | ||||
| CC | ||||
| CC | GO:0005912 | adherens junction | ||
| CC | GO:0005916 | fascia adherens | ||
| CC | GO:0015629 | actin cytoskeleton | ||
| CC | GO:0030016 | myofibril | ||
| CC | GO:0030018 | Z disc | ||
| CC | GO:0030027 | lamellipodium | ||
| CC | GO:0030175 | filopodium | ||
| CC | GO:0031252 | cell leading edge | ||
| CC | GO:0031674 | I band | ||
| CC | GO:0043229 | intracellular organelle | ||
| CC | ||||
| CC | GO:0043234 | protein complex | ||
| CC | GO:0043292 | contractile fibre | ||
| CC | GO:0070161 | anchoring junction | ||
| CC | GO:0070469 | respiratory chain | ||
| MF | GO:0003678 | DNA helicase activity | ||
| MF | GO:0003774 | motor activity | ||
| MF | GO:0003824 | catalytic activity | ||
| MF | GO:0003954 | NADH dehydrogenase activity | ||
| MF | GO:0004386 | helicase activity | ||
| MF | GO:0008137 | NADH dehydrogenase (ubiquinone) activity | ||
| MF | GO:0015078 | hydrogen ion transmembrane transporter activity | ||
| MF | GO:0016462 | pyrophosphatase activity | ||
| MF | GO:0016491 | oxidoreductase activity | ||
| MF | GO:0016817 | hydrolase activity, acting on acid anhydrides | ||
| MF | GO:0016818 | hydrolase activity, acting on acid anhydrides, in phosphorus-containing anhydrides | ||
| MF | GO:0017111 | nucleoside-triphosphatase activity | ||
| MF | GO:0046873 | metal ion transmembrane transporter activity | ||
a) List of GOs related to human ASD from Chang et al. (2015).
b) List of GOs in the aged BTBR mouse model from Jasien et al. (2014). GOs were determined based on statistical significance (p < 0.001). The p-value of each GO is shown in S8 and S9 Tables. GO enrichments from multiple studies are marked in bold.
GOs that exhibited significant concentration-dependent alterations among the ASD-related GOs suggested by previous studies.
| Category | Chang | Jasien | Term | ||
|---|---|---|---|---|---|
| Cortical | Hippocampal | ||||
| BP | 3.0e-5 | ||||
| BP | GO:0003008 | system process | 2.1e-11 | ||
| BP | GO:0006325 | chromatin organization | 2.3e-4 | ||
| BP | 9.5e-7 | ||||
| BP | GO:0006836 | neurotransmitter transport | 6.2e-5 | ||
| BP | GO:0006875 | cellular metal ion homeostasis | 4.6e-4 | ||
| BP | GO:0007187 | sarcolemma | 1.0e-6 | ||
| BP | GO:0007188 | adenylate cyclase-modulating G-protein coupled receptor signalling pathway | 2.6e-6 | ||
| BP | GO:0007267 | cell-cell signalling | 1.0e-4 | ||
| BP | 7.4e-6 | ||||
| BP | GO:0007613 | memory | 1.6e-4 | ||
| BP | GO:0016477 | cell migration | 3.5e-5 | ||
| BP | 4.1e-5 | ||||
| BP | GO:0023061 | signal release | 3.0e-5 | ||
| BP | GO:0030030 | cell projection organization | 5.0e-4 | ||
| BP | GO:0030705 | cytoskeleton-dependent intracellular transport | 7.7e-4 | ||
| BP | GO:0030799 | regulation of cyclic nucleotide metabolic process | 3.1e-4 | ||
| BP | GO:0030802 | regulation of cyclic nucleotide biosynthetic process | 2.7e-4 | ||
| BP | GO:0030808 | regulation of nucleotide biosynthetic process | 2.7e-4 | ||
| BP | GO:0030814 | regulation of cAMP metabolic process | 1.4e-4 | ||
| BP | GO:0030817 | regulation of cAMP biosynthetic process | 1.2e-4 | ||
| BP | 1.7e-6 | ||||
| BP | 2.2e-4 | ||||
| BP | GO:0040029 | regulation of gene expression, epigenetic | 2.8e-4 | ||
| BP | GO:0044707 | single-multicellular organism process | 8.1e-4 | ||
| BP | 1.3e-6 | ||||
| BP | GO:0048870 | cell motility | 1.6e-5 | ||
| BP | 5.6e-13 | ||||
| BP | GO:0051179 | localization | 1.2e-5 | ||
| BP | 4.8e-7 | ||||
| BP | GO:0051674 | localization of cell | 1.6e-5 | ||
| BP | GO:0055065 | metal ion homeostasis | 9.1e-4 | ||
| BP | GO:0055082 | cellular chemical homeostasis | 2.9e-4 | ||
| BP | GO:0065008 | regulation of biological quality | 4.6e-6 | ||
| BP | GO:0071944 | cell periphery | 2.6e-16 | ||
| CC | GO:0000785 | chromatin | 1.1e-7 | ||
| CC | GO:0005623 | cell | 5.0e-4 | ||
| CC | 2.3e-5 | ||||
| CC | 4.0e-5 | ||||
| CC | GO:0005856 | cytoskeleton | 4.9e-5 | ||
| CC | GO:0016023 | cytoplasmic membrane-bounded vesicle | 1.4e-4 | ||
| CC | GO:0031410 | cytoplasmic vesicle | 2.0e-4 | ||
| CC | GO:0031982 | vesicle | 9.1e-5 | ||
| CC | GO:0031988 | membrane-bounded vesicle | 9.3e-5 | ||
| CC | GO:0032991 | macromolecular complex | 3.2e-5 | ||
| CC | 7.2e-4 | ||||
| CC | 6.0e-4 | ||||
| CC | GO:0043226 | organelle | 1.8e-4 | ||
| CC | GO:0043229 | intracellular organelle | 1.7e-4 | ||
| CC | 7.2e-7 | ||||
| CC | GO:0044446 | intracellular organelle part | 4.9e-7 | ||
| CC | 2.7e-5 | ||||
| CC | 7.0e-7 | ||||
| CC | GO:0070161 | anchoring junction | 1.6e-5 | ||
| CC | GO:0070469 | respiratory chain | 2.7e-4 | ||
| MF | GO:0003824 | catalytic activity | 4.1e-5 | ||
| MF | GO:0004713 | protein tyrosine kinase activity | 6.3e-4 | ||
| MF | GO:0005216 | ion channel activity | 5.0e-4 | ||
| MF | GO:0005244 | voltage-gated ion channel activity | 3.2e-5 | ||
| MF | GO:0005261 | cation channel activity | 6.9e-4 | ||
| MF | GO:0015078 | hydrogen ion transmembrane transporter activity | 3.5e-4 | ||
| MF | GO:0015276 | ligand-gated ion channel activity | 1.5e-6 | ||
| MF | GO:0019905 | syntaxin binding | 1.6e-4 | ||
| MF | GO:0022832 | voltage-gated channel activity | 4.0e-5 | ||
| MF | GO:0022834 | ligand-gated channel activity | 1.5e-6 | ||
| MF | GO:0022836 | gated channel activity | 9.9e-6 | ||
| MF | GO:0022838 | substrate-specific channel activity | 5.8e-5 | ||
| MF | GO:0022843 | voltage-gated cation channel activity | 5.7e-5 | ||
| MF | GO:0046873 | metal ion transmembrane transporter activity | 1.0e-5 | ||
a) List of GOs related to human ASD from Chang et al. (2015).
b) List of GOs in the aged BTBR mouse model from Jasien et al. (2014). GO enrichments from multiple studies are marked in bold.